Afexa Life Sciences Inc.
TSX : CVQ

Afexa Life Sciences Inc.

August 27, 2007 08:00 ET

CV Technologies Appoints New Director

EDMONTON, ALBERTA--(Marketwire - Aug. 27, 2007) - CV Technologies Inc. (TSX:CVQ) is pleased to announce that Maurice (Ted) Bilyea of Toronto has accepted an invitation to join its Board of Directors. Mr. Bilyea's appointment is effective today. This appointment fills a vacancy and brings the Board complement to eight Directors.

Mr. Bilyea was formerly Executive Vice-President of Maple Leaf Foods Inc. and, prior to that, President of Maple Leaf Foods International. He holds a B.A. (Hons.) and an M.A. in International Relations from York University in Ontario. Mr. Bilyea is the Deputy Chair of the Science Advisory Board of Agriculture and Agri-food Canada and was Co-Chair of the Canadian Agri-food Marketing Council which advised the federal Ministers of Agriculture and Trade.

"We are delighted to welcome Mr. Bilyea to our Board," said Gordon Tallman, Chairman of the Board of Directors of CV Technologies. "His domestic as well as international business expertise along with his extensive consumer products industry knowledge gleaned in over 35 years working in the industry will be a valuable resource as we develop and execute our new business plan."

ABOUT CV TECHNOLOGIES INC.

CV Technologies is a global leader in the development and commercialization of naturally derived, evidence-based, natural therapeutics for disease prevention and health maintenance. Its lead product - COLD-fX® - approved by Health Canada, prevents and relieves cold and flu infections by strengthening the immune system. It is Canada's #1 selling cold and flu remedy (ACNielsen's MarketTrack Drug Service for Cold Remedies, Natural Supplements & Vitamins Categories for the 52 weeks ending June 9, 2007).

This news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results or events to differ materially from the results or events predicted in this release. Potential risks and uncertainties include, without limitation, those associated with product development, future revenues and profitability related to the development and execution of the Company's new business plan. For a more in-depth account of risks and uncertainties, please refer to documents filed with the Canadian securities regulatory authorities through the System for Electronic Document Analysis and Retrieval (SEDAR). Subject to its obligations under applicable law, the Company assumes no duty to update this disclosure. The Company is a 12g3-2(b) SEC registrant.

Contact Information